Concord Biotech Limited

NSE CONCORDBIO.NS

Concord Biotech Limited Gross Profit Margin for the year ending March 31, 2024: 75.47%

Concord Biotech Limited Gross Profit Margin is 75.47% for the year ending March 31, 2024, a -4.32% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • Concord Biotech Limited Gross Profit Margin for the year ending March 31, 2023 was 78.88%, a 5.33% change year over year.
  • Concord Biotech Limited Gross Profit Margin for the year ending March 31, 2022 was 74.89%, a -6.49% change year over year.
  • Concord Biotech Limited Gross Profit Margin for the year ending March 31, 2021 was 80.08%, a 9.63% change year over year.
  • Concord Biotech Limited Gross Profit Margin for the year ending March 31, 2020 was 73.05%.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
SV Wall Street
NSE: CONCORDBIO.NS

Concord Biotech Limited

CEO Mr. Ankur Vaid
IPO Date Aug. 18, 2023
Location India
Headquarters 16th Floor, B-Wing
Employees 1,377
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

StockViz Staff

February 6, 2025

Any question? Send us an email